Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06469151 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults

A Phase 1 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
84
Enrollment target

NCT06469151: Completed Phase 1 study, sponsored by AstraZeneca.

NCT06469151 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 84 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06469151, a Phase 1 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
84 participants
Enrollment target

Study Summary

The purpose of this study is to measure safety, tolerability, and pharmacokinetics (PK) of a single dose of AZD5148 administered via intravenous (IV) bolus or intramuscular (IM) injection in healthy participants

Primary Outcome

To evaluate the safety and tolerability of AZD5148 administered as a single IV or IM dose to healthy adult participants.

Interventions

  • DRUG Placebo
  • DRUG AZD5148

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2024-06-24
Est. Completion 2025-10-22
Phase Phase 1
AstraZeneca

1,285 total trials

What the finished NCT06469151 record still lists

NCT06469151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT06469151 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06469151 about?

NCT06469151 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults". The purpose of this study is to measure safety, tolerability, and pharmacokinetics (PK) of a single dose of AZD5148 administered via intravenous (IV) bolus or intramuscular (IM) injection in healthy participants

What is the current status of trial NCT06469151?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2024-06-24. Estimated completion is 2025-10-22.

What interventions are being tested in trial NCT06469151?

The interventions under investigation include: Placebo (DRUG), AZD5148 (DRUG).

Who is sponsoring clinical trial NCT06469151?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06469151's enrollment target sits among peer trials

84 659th of 2000 higher than 1,336 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02391519 · 84 participants

    Effects of High Altitude on AMPK Activation

  • NCT03838536 · 84 participants · NA

    Synergistic Activity of Human Milk Nutrients and Infant Cognition

  • NCT03884075 · 84 participants · Phase 2

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

  • NCT03894917 · 84 participants

    Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06469151, the US trial registry maintained by the National Library of Medicine. NCT06469151 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.